The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Desmopressin (Noqdirna®) has been accepted for restricted in the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. The restriction limits use to adults aged 65 years and over.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Hepatitis B added to Routine Immunisation Schedule||Drug Safety Update - August 2017 »|